New Xtandi data bolster case for pre-chemo use
This article was originally published in Scrip
Executive Summary
Astellas and Medivation reported a 10-month progression-free survival benefit for Xtandi (enzalutamide) versus Casodex (bicalutamide) in a Phase II clinical trial designed to satisfy requests for a head-to-head comparison of the androgen receptor inhibitors in metastatic castrate-resistant prostate cancer (mCRPC).
You may also be interested in...
Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation
As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.